Introduction: Prostate cancer (PCa) is a major public health issue in men older than 40 years old. New genetic diagnostic markers like DD3 and racemase (AMACR) have been the subject of several studies in prostate cancer. Still, the real value of these markers in terms of prognosis has not been studied yet. Objectives: To describe and correlate DD3 and AMACR gene expression in PCa patients who underwent radical retropubic prostatectomy (RRP) and to compare their expression in patients with localized and advanced tumors. Methods: Forty-two prostate samples were collected. DD3 and AMACR gene expression were measured by Reverse Transcription Polymerase Chain Reaction (RT-PCR). Clinical and pathological data were obtained from the patient’s registry. Results: DD3 and AMACR did not correlate with the pathological stage. Spearman’s correlation coefficient was ρ = ？0.15 (p = 0.39) and ρ = 0.17 (p = 0.49) for DD3 and AMACR, respectively. The mean difference in DD3 expression between localized and advanced disease was 0.74 (CI: ？0.70 - 0.21; p = 0.30); the mean difference in AMACR between groups was 0.11 (CI: ？0.32 - 0.10; p = 0.28). Conclusions: Comparison of gene expression between localized and advanced tumors has not shown significant differences. Correlation among different pathological groups was not important. DD3 and AMACR, although expressed in prostate cancer tissue, cannot be used as prognostic markers based on pathological staging.
References
[1]
National Cancer Institute-INCA (Brazil) (2008) Cancer Incidence in Brazil-2008 Esti-Mation. Department of Health.
[2]
Nelen, V. (2007) Epidemiology of Prostate Cancer. In: Ramon, J. and Denis, L.J., Eds., Recent Results in Cancer Research, Springer Berlin Heidelberg, 1-8. https://doi.org/10.1007/978-3-540-40901-4_1
[3]
Carter, H.B., Allaf, M.E. and Partin, A.W. (2007) Diagnosis and Staging of Prostate Cancer. In: Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. and Wein, A.J., Eds., Camp-Bell-Walsh Urology, 9th Edition, Saunders-Elsevier, 2912-2931.
[4]
Hochreiter, W.W. (2008) The Issue of Prostate Cancer Evaluation in Men with Elevated Prostate-Specific Antigen and Chronic Prostatitis. Andrologia, 40, 130-133. https://doi.org/10.1111/j.1439-0272.2007.00820.x
[5]
Steinberg, G.D., Carter, B.S., Beaty, T.H., Childs, B. and Walsh, P.C. (1990) Family History and the Risk of Prostate Cancer. The Prostate, 17, 337-347. https://doi.org/10.1002/pros.2990170409
[6]
Carter, B.S., Beaty, T.H., Steinberg, G.D., Childs, B. and Walsh, P.C. (1992) Mendelian Inheritance of Familial Prostate Cancer. Proceedings of the National Academy of Sciences, 89, 3367-3371. https://doi.org/10.1073/pnas.89.8.3367
[7]
Ross, R.K., Bernstein, L., Pike, M.C., Henderson, B.E., Lobo, R.A., Stanczyk, F.Z., et al. (1992) 5-Alpha-Reductase Activity and Risk of Prostate Cancer among Japanese and US White and Black Males. The Lancet, 339, 887-889. https://doi.org/10.1016/0140-6736(92)90927-u
[8]
Henderson, B.E. and Feigelson, H.S. (2000) Hormonal Carcinogenesis. Carcinogenesis, 21, 427-433. https://doi.org/10.1093/carcin/21.3.427
[9]
de Kok, J.B., Verhaegh, G.W., Roelofs, R.W., Hessels, D., Kiemeney, L.A., Aalders, T.W., et al. (2002) DD3, a Very Sensitive and Specific Marker to Detect Prostate Tumors. Cancer Research, 62, 2695-2698.
[10]
Catalona, W.J. and Han, M. (2007) Definitive Therapy for Localized Prostate Cancer —An Overview. In: Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. and Wein, A.J., Eds., Campbell-Walsh Urology, 9th Edition, Saunders-Elsevier, 2932-2946.
[11]
Sardana, G., Dowell, B. and Diamandis, E.P. (2008) Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. Clinical Chemistry, 54, 1951-1960. https://doi.org/10.1373/clinchem.2008.110668
[12]
Hessels, D., Klein Gunnewiek, J.M.T., van Oort, I., Karthaus, H.F.M., van Leenders, G.J.L., van Balken, B., et al. (2003) DD3PCA3-Based Molecular Urine Analysis for the Diagnosis of Prostate Cancer. European Urology, 44, 8-16. https://doi.org/10.1016/s0302-2838(03)00201-x
[13]
Schalken, J.A., Hessels, D. and Verhaegh, G. (2003) New Targets for Therapy in Prostate Cancer: Differential Display Code 3 (DD3PCA3), a Highly Prostate Cancer-Specific Gene. Urology, 62, 34-43. https://doi.org/10.1016/s0090-4295(03)00759-3
[14]
Gandini, O., Luci, L., Stigliano, A., Lucera, R., Di Silverio, F., Toscano, V., et al. (2003) Is DD3 a New Prostate-Specific Gene? Anticancer Research, 23, 305-308.
[15]
Trojan, L., Schaaf, A., Steidler, A., Haak, M., Thalmann, G., Knoll, T., et al. (2005) Identification of Metastasis-Associated Genes in Prostate Cancer by Genetic Profiling of Human Prostate Cancer Cell Lines. Anticancer Research, 25, 183-191.
[16]
van Moorselaar, R.J.A. and Voest, E.E. (2002) Angiogenesis in Prostate Cancer: Its Role in Disease Progression and Possible Therapeutic Approaches. Molecular and Cellular Endocrinology, 197, 239-250. https://doi.org/10.1016/s0303-7207(02)00262-9
[17]
Murphy, A.J., Hughes, C.A., Lannigan, G., Sheils, O., O’Leary, J. and Loftus, B. (2007) Heterogeneous Expression of α‐Methylacyl‐CoA Racemase in Prostatic Cancer Correlates with Gleason Score. Histopathology, 50, 243-251. https://doi.org/10.1111/j.1365-2559.2007.02572.x
[18]
Adley, B.P. and Yang, X.J. (2006) Application of Alpha-Methylacyl Coenzyme A Racemase Immunohistochemistry in the Diagnosis of Prostate Cancer: A Review. Analytical and Quantitative Cytology and Histology, 28, 1-13.
[19]
Zehentner, B.K., Secrist, H., Zhang, X., Hayes, D.C., Ostenson, R., Goodman, G., et al. (2006) Detection of Α-Methylacyl-Coenzyme-A Racemase Transcripts in Blood and Urine Samples of Prostate Cancer Patients. Molecular Diagnosis & Therapy, 10, 397-403. https://doi.org/10.1007/bf03256217
[20]
Rubin, M.A. (2002) α-Methylacyl Coenzyme a Racemase as a Tissue Biomarker for Prostate Cancer. JAMA, 287, 1662-1670. https://doi.org/10.1001/jama.287.13.1662
[21]
Amling, C.L., Blute, M.L., Bergstralh, E.J., Seay, T.M., Slezak, J. and Zincke, H. (2000) Long-Term Hazard of Progression after Radical Prostatectomy for Clinically Localized Prostate Cancer: Continued Risk of Biochemical Failure after 5 Years. Journal of Urology, 164, 101-105. https://doi.org/10.1016/s0022-5347(05)67457-5
[22]
Pettus, J.A., Weight, C.J., Thompson, C.J., Middleton, R.G. and Stephenson, R.A. (2004) Biochemical Failure in Men Following Radical Retropubic Prostatectomy: Impact of Surgical Margin Status and Location. Journal of Urology, 172, 129-132. https://doi.org/10.1097/01.ju.0000132160.68779.96
[23]
Taskén, K.A., Angelsen, A., Svindland, A., Eide, T., Berge, V., Wahlquist, R. and Karlsen, S. (2005) Markers for Diagnosis, Prediction and Prognosis of Prostate Cancer. Tidsskr Nor Laegeforen, 125, 3279-3282.
[24]
Schenk-Braat, E.A. and Bangma, C.H. (2006) The Search for Better Markers for Prostate Cancer than Prostate-Specific Antigen. NederlandsTijdschriftvoorGeneeskunde, 150, 1286-1290.
[25]
Tao, Z.H., Mao, X.L., Wang, C.H., Chen, X.D., Yu, K.Y., Weng, Z.L., et al. (2007) Quantitative Detection of DD3 mRNA in Prostate Cancer Tissues by Real-Time Fluorescent Quantitative Reverse Transcription Polymerase Chain Reaction. National Journal of Andrology, 13, 130-133.
[26]
Bialkowska-Hobrzanska, H., Driman, D.K., Fletcher, R., Harry, V. and Razvi, H. (2006) Expression of Human Telomerase Reverse Transcriptase, Survinin DD3 and PCGEM1 Messenger RNA in Archival Prostate Carcinoma Tissue. The Canadian Journal of Urology, 13, 2967-2974.
[27]
Zielie, P.J., Mobley, J.A., Ebb, R.G., Jiang, Z., Blute, R.D. and Ho, S.M. (2004) A Novel Diagnostic Test for Prostate Cancer Emerges from the Determination of α-Methylacyl-Coenzyme A Racemase in Prostatic Secretions. Journal of Urology, 172, 1130-1133. https://doi.org/10.1097/01.ju.0000133560.87118.4d
[28]
Stewart, J., Fleshner, N., Cole, H., Toi, A. and Sweet, J. (2008) Prognostic Significance of α-Methylacyl-CoA Racemase among Men with High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies. Journal of Urology, 179, 1751-1755. https://doi.org/10.1016/j.juro.2008.01.012
[29]
Rubin, M.A., Bismar, T.A., Andrén, O., Mucci, L., Kim, R., Shen, R., et al. (2005) Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer Is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. Cancer Epidemiology, Biomarkers & Prevention, 14, 1424-1432. https://doi.org/10.1158/1055-9965.epi-04-0801
